Osteoporosis is a disease that affects 35% women and 20% men aged more than 65 years. Reduction in bone formation and increased bone resorption are known factors that drive osteoporosis, but recent studies suggest a positive correlation between bone marrow adipose tissue (MAT) and osteoporosis. Previously, we have observed that tonsil-derived mesenchymal stem cells (T-MSCs) reduce MAT in a mouse model of bone marrow depletion. That prompted us to investigate on the senile osteoporosis to characterize the bone-forming effect, as well as MAT-reducing effect of T-MSCs. In a mouse model of senescence-accelerated mouse prone 6 (SAMP6), we injected T-MSCs or T-MSC conditioned medium (CM) through tail vein and examined changes in bone microstructure using micro-CT scan and hematoxylin & eosin (H&E) staining. Biochemical markers of osteoporosis, deoxypyridinoline (DPD) and osteocalcin, were examined by ELISA. Results demonstrated attenuation in the progression of osteoporosis, in part, by sustaining osteocalcin production and by blocking MAT accumulation. Increase in matrix mineralization was determined using in vitro culture of murine preosteoblast cell line by treatment of T-MSC CM. Interestingly, T-MSC CM induced continuous weight loss and selectively reduced visceral adipose tissue mass. Finally, antiadipogenic effects of T-MSC CM were determined in vitro. In conclusion, regulation of bone together with MAT could be considered as a new therapeutic option for the treatment of senile osteoporosis and this report may provide a framework for future cell therapy using T-MSCs.
Get full access to this article
View all access options for this article.
References
1.
KawaiM, ModderUI, KhoslaS and RosenCJ. (2011). Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov, 10:141–156.
2.
RossouwJE, AndersonGL, PrenticeRL, LaCroixAZ, KooperbergC, StefanickML, JacksonRD, BeresfordSA, HowardBV, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288:321–333.
3.
Barrett-ConnorE, MoscaL, CollinsP, GeigerMJ, GradyD, KornitzerM, McNabbMA and WengerNK. (2006). Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med, 355:125–137.
4.
KhoslaS, BurrD, CauleyJ, DempsterDW, EbelingPR, FelsenbergD, GagelRF, GilsanzV, GuiseT, et al. (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 22:1479–1491.
5.
AbrahamsenB, EikenP and EastellR. (2009). Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res, 24:1095–1102.
6.
Lecka-CzernikB. (2010). Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep, 8:178–184.
7.
JustesenJ, StenderupK, EbbesenEN, MosekildeL, SteinicheT and KassemM. (2001). Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology, 2:165–171.
8.
DevlinMJ, CloutierAM, ThomasNA, PanusDA, LotinunS, PinzI, BaronR, RosenCJ and BouxseinML. (2010). Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res, 25:2078–2088.
9.
PatschJM, LiX, BaumT, YapSP, KarampinosDC, SchwartzAV and LinkTM. (2013). Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res, 28:1721–1728.
10.
RosenCJ and BouxseinML. (2006). Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol, 2:35–43.
11.
TakadaI, KouzmenkoAP and KatoS. (2009). Wnt and PPAR[gamma] signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol, 5:442–447.
12.
MuruganandanS, RomanAA and SinalCJ. (2009). Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci, 66:236–253.
13.
WeiW, DutchakPA, WangX, DingX, WangX, BookoutAL, GoetzR, MohammadiM, GerardRD, et al. (2012). Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A, 109:3143–3148.
14.
Negishi-KogaT, ShinoharaM, KomatsuN, BitoH, KodamaT, FriedelRH and TakayanagiH. (2011). Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med, 17:1473–1480.
15.
HayashiM, NakashimaT, TaniguchiM, KodamaT, KumanogohA and TakayanagiH. (2012). Osteoprotection by semaphorin 3A. Nature, 485:69–74.
16.
RyuKH, ChoKA, ParkHS, KimJY, WooSY, JoI, ChoiYH, ParkYM, JungSC, et al. (2012). Tonsil-derived mesenchymal stromal cells: evaluation of biologic, immunologic and genetic factors for successful banking. Cytotherapy, 14:1193–1202.
17.
ParkM, KimYH, WooSY, LeeHJ, YuY, KimHS, ParkYS, JoI, ParkJW, et al. (2015). Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation. Sci Rep, 5:8616.
18.
ZhouL and OgataY. (2013). Transcriptional regulation of the human bone sialoprotein gene by fibroblast growth factor 2. J Oral Sci, 55:63–70.
19.
KimS, AhnC, BongN, ChoeS and LeeDK. (2015). Biphasic effects of FGF2 on adipogenesis. PLoS One, 10:e0120073.
20.
TakadaK, InabaM, IchiokaN, UedaY, TairaM, BabaS, MizokamiT, WangX, HishaH, IidaH and IkeharaS. (2006). Treatment of senile osteoporosis in SAMP6 mice by intra-bone marrow injection of allogeneic bone marrow cells. Stem Cells, 24:399–405.
21.
MirsaidiA, GenelinK, VetschJR, StangerS, TheissF, LindtnerRA, von RechenbergB, BlauthM, MüllerR, et al. (2014). Therapeutic potential of adipose-derived stromal cells in age-related osteoporosis. Biomaterials, 35:7326–7335.
22.
ChoKA, WooSY, ParkYS, ParkMH and RyuKH. (2012). Macrophage inflammatory protein-2 (MIP-2)/CXCR2 blockade attenuates acute graft-versus-host disease while preserving graft-versus-leukemia activity. Biochem Biophys Res Commun, 426:558–564.
23.
SamivelR, KimEH, ChungYJ and MoJH. (2015). Immunomodulatory effect of tonsil-derived mesenchymal stem cells in a mouse model of allergic rhinitis. Am J Rhinol Allergy, 29:262–267.
24.
TakedaT. (1999). Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol Aging, 20:105–110.
25.
MatsushitaM, TsuboyamaT, KasaiR, OkumuraH, YamamuroT, HiguchiK, HiguchiK, KohnoA, YonezuT, et al. (1986). Age-related changes in bone mass in the senescence-accelerated mouse (SAM). SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis. Am J Pathol, 125:276–283.
26.
KajkenovaO, Lecka-CzernikB, GubrijI, HauserSP, TakahashiK, ParfittAM, JilkaRL, ManolagasSC and LipschitzDA. (1997). Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res, 12:1772–1779.
27.
IchiokaN, InabaM, KushidaT, EsumiT, TakaharaK, InabaK, OgawaR, IidaH and IkeharaS. (2002). Prevention of senile osteoporosis in SAMP6 mice by intrabone marrow injection of allogeneic bone marrow cells. Stem Cells, 20:542–551.
28.
BotolinS and McCabeLR. (2006). Inhibition of PPARγ prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol, 209:967–976.
29.
NaveirasO, NardiV, WenzelPL, HauschkaPV, FaheyF and DaleyGQ. (2009). Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature, 460:259–263.
30.
YuY, ParkYS, KimHS, KimHY, JinYM, JungSC, RyuKH and JoI. (2014). Characterization of long-term in vitro culture-related alterations of human tonsil-derived mesenchymal stem cells: role for CCN1 in replicative senescence-associated increase in osteogenic differentiation. J Anat, 225:510–518.
31.
LiuLF, ShenWJ, UenoM, PatelS and KraemerFB. (2011). Characterization of age-related gene expression profiling in bone marrow and epididymal adipocytes. BMC Genomics, 12:212.
32.
JanjaninS, DjouadF, ShantiRM, BakshD, GollapudiK, PrgometD, RackwitzL, JoshiAS and TuanRS. (2008). Human palatine tonsil: a new potential tissue source of multipotent mesenchymal progenitor cells. Arthritis Res Ther, 10:R83.
33.
KimSY, KimYR, ParkWJ, KimHS, JungSC, WooSY, JoI, RyuKH and ParkJW. (2015). Characterisation of insulin-producing cells differentiated from tonsil derived mesenchymal stem cells. Differentiation, 90:27–39.
34.
ParkYS, KimHS, JinYM, YuY, KimHY, ParkHS, JungSC, HanKH, ParkYJ, RyuKH and JoI. (2015). Differentiated tonsil-derived mesenchymal stem cells embedded in Matrigel restore parathyroid cell functions in rats with parathyroidectomy. Biomaterials, 65:140–152.
35.
ParkM, KimYH, RyuJH, WooSY and RyuKH. (2015). Immune suppressive effects of tonsil-derived mesenchymal stem cells on mouse bone-marrow-derived dendritic cells. Stem Cells Int, 2015:106540.
36.
RyuJH, ParkM, KimBK, RyuKH and WooSY. (2015). Tonsil-derived mesenchymal stromal cells produce CXCR2-binding chemokines and acquire follicular dendritic cell-like phenotypes under TLR3 stimulation. Cytokine, 73:225–235.
37.
OgataY. (2008). Bone sialoprotein and its transcriptional regulatory mechanism. J Periodontal Res, 43:127–135.
38.
NakayamaY, NakajimaY, KatoN, TakaiH, KimDS, AraiM, MezawaM, ArakiS, SodekJ and OgataY. (2006). Insulin-like growth factor-I increases bone sialoprotein (BSP) expression through fibroblast growth factor-2 response element and homeodomain protein-binding site in the proximal promoter of the BSP gene. J Cell Physiol, 208:326–335.
39.
MezawaM, ArakiS, TakaiH, SasakiY, WangS, LiX, KimDS, NakayamaY and OgataY. (2009). Regulation of human bone sialoprotein gene transcription by platelet-derived growth factor-BB. Gene, 435:80–87.
40.
KringsA, RahmanS, HuangS, LuY, CzernikPJ and Lecka-CzernikB. (2012). Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone, 50:546–552.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
